- Winter is Coming: How a Labor Case in SCOTUS Impacts FDA Injunction Powers July 3, 2024
- Former DEA Administrators Weigh in on Marijuana Rescheduling July 1, 2024
- RAPS Convergence 2024 to Feature Session on Accelerating Breakthrough Device Commercialization — Led by HPM Medical Device Regulatory Expert Adrienne Lenz July 1, 2024
- Pharmacists in Florida (and Elsewhere): Waive Prescribing Red Flags at Your Peril June 28, 2024
- PreSTAR: a New Template for Pre Submissions and 513(g) Requests for Information June 27, 2024
- Big Molecule Watch Blog
- Bloomberg BNA Health Care Blog
- Drug and Device Law Blog
- Eye on FDA
- FDA Matters
- Harvard Law Bill of Health
- IN VIVO Blog
- Internet Drug News.com
- Lachman Consultants Blog
- Medical Devices Today
- Orange Book Blog
- The Orange Book Insights Blog
- Pharma IQ
- Pharmalot
- SCOTUS Blog
- The Volokh Conspiracy
- WLF Legal Pulse
- Advertising and Promotion (Federal Trade Commission)
- Advertising and Promotion (OPDP)
- Animal Drugs and Feeds
- Biosimilars
- Cannabis
- cGMP Compliance
- Consumer Product Safety Commission
- Controlled Substances
- Cosmetics
- COVID19
- Current Affairs
- Dietary Supplements
- Drug Development
- Drug Enforcement Administration
- Enforcement
- FDA News
- Foods
- Foods and Dietary Supplements
- Fraud and Abuse
- Government Pricing
- Hatch-Waxman
- Health Care
- Health Privacy
- Import/Export
- In Vitro Diagnostic Devices
- Jobs
- Medical Devices
- Miscellaneous
- Orphan Drugs
- OTC Drugs and Cosmetics
- Prescription Drugs and Biologics
- Product Jurisdiction and Combination Products
- Reimbursement
- Tissue Products
- Tobacco
- Uncategorized
HPM Posts Summary of H.R. 3962 Provisions Directly Affecting Drug and Device Manufacturers
November 2, 2009By Alan M. Kirschenbaum & Kurt R. Karst –
Last Thursday we reported on the release by the House of H.R. 3962, the health care reform bill that will soon be considered on the House floor. As we have done with other health care reform proposals, we have prepared a summary of the provisions of H.R. 3962 that are of direct interest to pharmaceutical and medical device manufacturers. Our summary can be found here. The full text of the bill can be found here.
Search FDA Law Blog
Subscribe
Latest Tweets
Tweets by @fdalawblogAwards & Honors
- The Best
Lawyers in America
US News & World Report - Ranked in Chambers USA 2018
- Winter is Coming: How a Labor Case in SCOTUS Impacts FDA Injunction Powers July 3, 2024
- Former DEA Administrators Weigh in on Marijuana Rescheduling July 1, 2024
- RAPS Convergence 2024 to Feature Session on Accelerating Breakthrough Device Commercialization — Led by HPM Medical Device Regulatory Expert Adrienne Lenz July 1, 2024
- Pharmacists in Florida (and Elsewhere): Waive Prescribing Red Flags at Your Peril June 28, 2024
- PreSTAR: a New Template for Pre Submissions and 513(g) Requests for Information June 27, 2024
- Big Molecule Watch Blog
- Bloomberg BNA Health Care Blog
- Drug and Device Law Blog
- Eye on FDA
- FDA Matters
- Harvard Law Bill of Health
- IN VIVO Blog
- Internet Drug News.com
- Lachman Consultants Blog
- Medical Devices Today
- Orange Book Blog
- The Orange Book Insights Blog
- Pharma IQ
- Pharmalot
- SCOTUS Blog
- The Volokh Conspiracy
- WLF Legal Pulse
- Advertising and Promotion (Federal Trade Commission)
- Advertising and Promotion (OPDP)
- Animal Drugs and Feeds
- Biosimilars
- Cannabis
- cGMP Compliance
- Consumer Product Safety Commission
- Controlled Substances
- Cosmetics
- COVID19
- Current Affairs
- Dietary Supplements
- Drug Development
- Drug Enforcement Administration
- Enforcement
- FDA News
- Foods
- Foods and Dietary Supplements
- Fraud and Abuse
- Government Pricing
- Hatch-Waxman
- Health Care
- Health Privacy
- Import/Export
- In Vitro Diagnostic Devices
- Jobs
- Medical Devices
- Miscellaneous
- Orphan Drugs
- OTC Drugs and Cosmetics
- Prescription Drugs and Biologics
- Product Jurisdiction and Combination Products
- Reimbursement
- Tissue Products
- Tobacco
- Uncategorized